138 related articles for article (PubMed ID: 29024542)
1. The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.
Xin Y; Shao L; Maltzman J; Stefanidis D; Hemenway J; Tarnowski T; Deng W; Silverman JA
Clin Pharmacol Drug Dev; 2018 Mar; 7(3):277-286. PubMed ID: 29024542
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
Thomson AB; Kirdeikis P; Lastiwka R; Röhss K; Sinclair P; Olofsson B
Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
[TBL] [Abstract][Full Text] [Related]
3. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
[TBL] [Abstract][Full Text] [Related]
4. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Xin Y; Kawashima J; Weng W; Kwan E; Tarnowski T; Silverman JA
J Clin Pharmacol; 2018 Apr; 58(4):522-532. PubMed ID: 29283448
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
7. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions.
Thomson AB; Sinclair P; Matisko A; Rosen E; Andersson T; Olofsson B
Can J Gastroenterol; 1997; 11(8):663-7. PubMed ID: 9459045
[TBL] [Abstract][Full Text] [Related]
8. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC
J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526
[TBL] [Abstract][Full Text] [Related]
9. Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
Salem AH; Agarwal SK; Dunbar M; Nuthalapati S; Chien D; Freise KJ; Wong SL
J Clin Pharmacol; 2016 Nov; 56(11):1355-1361. PubMed ID: 27029823
[TBL] [Abstract][Full Text] [Related]
10. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
12. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
15. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
16. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
Islam MS; Trini AB; Shohag H; Ahmed MU; Maruf AA; Hasnat A
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
[TBL] [Abstract][Full Text] [Related]
18. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule.
Schaltenbrand R; Huber R; Cotoraci CA; Mascher H; Potthast H; Hole U
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):453-9. PubMed ID: 11680670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
